NEW YORK and MELBOURNE, Australia, Nov. 13, 2013 -- Regenerative medicine company Mesoblast Limited today announced that a peer-reviewed article in the November 2013 issue of the scientific journal Biology of Blood and Marrow Transplantation has shown that use of its proprietary culture-expanded Mesenchymal Stem Cell product, Prochymal , resulted ... (more)
http://www.globenewswire.com/news-release/2013/11/14/589696/10057954/en/IMPROVED-SURVIVAL-IN-CHILDREN-WITH-LIFE-THREATENING-GRAFT-VERSUS-HOST-DISEASE-REPORTED-AFTER-TREATMENT-WITH-MESOBLAST-S-CELL-THERAPY.html
http://www.globenewswire.com/news-release/2013/11/14/589696/10057954/en/IMPROVED-SURVIVAL-IN-CHILDREN-WITH-LIFE-THREATENING-GRAFT-VERSUS-HOST-DISEASE-REPORTED-AFTER-TREATMENT-WITH-MESOBLAST-S-CELL-THERAPY.html
No comments:
Post a Comment